ALB and non-small cell lung carcinoma: We note that, in our population, patients with driver-driven NSCLC receiving targeted therapies are less likely to have albumin < 35 g/L than those without a driver aberration treated with immunotherapy regimens (36% versus 48%, respectively (p = 0.026)) [14].